Absci Corp
NASDAQ:ABSI
Intrinsic Value
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. [ Read More ]
The intrinsic value of one ABSI stock under the Base Case scenario is 1.97 USD. Compared to the current market price of 4.91 USD, Absci Corp is Overvalued by 60%.
Valuation Backtest
Absci Corp
Run backtest to discover the historical profit from buying and selling ABSI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Absci Corp
Current Assets | 120.6m |
Cash & Short-Term Investments | 97.7m |
Receivables | 2.2m |
Other Current Assets | 20.7m |
Non-Current Assets | 96.7m |
PP&E | 45.8m |
Intangibles | 48.3m |
Other Non-Current Assets | 2.6m |
Current Liabilities | 29.6m |
Accounts Payable | 1.5m |
Accrued Liabilities | 21m |
Other Current Liabilities | 7.1m |
Non-Current Liabilities | 11.6m |
Long-Term Debt | 4.7m |
Other Non-Current Liabilities | 6.8m |
Earnings Waterfall
Absci Corp
Revenue
|
5.7m
USD
|
Operating Expenses
|
-99.9m
USD
|
Operating Income
|
-94.2m
USD
|
Other Expenses
|
-16.4m
USD
|
Net Income
|
-110.6m
USD
|
Free Cash Flow Analysis
Absci Corp
ABSI Profitability Score
Profitability Due Diligence
Absci Corp's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Absci Corp's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
ABSI Solvency Score
Solvency Due Diligence
Absci Corp's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Absci Corp's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABSI Price Targets Summary
Absci Corp
According to Wall Street analysts, the average 1-year price target for ABSI is 8.77 USD with a low forecast of 6.06 USD and a high forecast of 13.65 USD.
Ownership
ABSI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ABSI Price
Absci Corp
Average Annual Return | -67.15% |
Standard Deviation of Annual Returns | 8.1% |
Max Drawdown | -96% |
Market Capitalization | 553.8m USD |
Shares Outstanding | 112 785 000 |
Percentage of Shares Shorted | 11.33% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.
Contact
IPO
Employees
Officers
The intrinsic value of one ABSI stock under the Base Case scenario is 1.97 USD.
Compared to the current market price of 4.91 USD, Absci Corp is Overvalued by 60%.